Cargando…

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Samkari, Hanny, Kasthuri, Raj S., Parambil, Joseph G., Albitar, Hasan A., Almodallal, Yahya A., Vázquez, Carolina, Serra, Marcelo M., Dupuis-Girod, Sophie, Wilsen, Craig B., McWilliams, Justin P., Fountain, Evan H., Gossage, James R., Weiss, Clifford R., Latif, Muhammad A., Issachar, Assaf, Mei-Zahav, Meir, Meek, Mary E., Conrad, Miles, Rodriguez-Lopez, Josanna, Kuter, David J., Iyer, Vivek N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327711/ https://www.ncbi.nlm.nih.gov/pubmed/32675221 http://dx.doi.org/10.3324/haematol.2020.261859

Ejemplares similares

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
por: Parambil, Joseph G., et al.
Publicado: (2021)

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
por: Faughnan, Marie E., et al.
Publicado: (2018)

Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia
por: Bloom, Patricia P., et al.
Publicado: (2020)

Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
por: Kritharis, Athena, et al.
Publicado: (2018)

A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders
por: Al‐Samkari, Hanny, et al.
Publicado: (2020)

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
por: Albitar, Hasan Ahmad, et al.
Publicado: (2020)

Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Ou, George, et al.
Publicado: (2016)

Predictors of heart failure symptoms in hereditary hemorrhagic telangiectasia patients with hepatic arteriovenous malformations
por: Cusumano, Lucas R., et al.
Publicado: (2021)

Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature
por: Dupuis, Olivier, et al.
Publicado: (2020)

Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding
por: Beckman, Joan D., et al.
Publicado: (2020)

HiBiT-qIP, HiBiT-based quantitative immunoprecipitation, facilitates the determination of antibody affinity under immunoprecipitation conditions
por: Ranawakage, Deshani C., et al.
Publicado: (2019)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Significant Hematochezia and Intracranial Bleeding in Neonatal Hereditary Hemorrhagic Telangiectasia
por: Merves, Matthew, et al.
Publicado: (2019)

A case report of unexplained jejunal telangiectasia complicated with bleeding
por: Zhang, Wen-jun, et al.
Publicado: (2020)

Tamoxifen Therapy for Recurrent Mucosal Bleeding in Hereditary Hemorrhagic Telangiectasia
por: Yung, Stephanie, et al.
Publicado: (2021)

Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
por: Masood, Muaaz, et al.
Publicado: (2021)

Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
por: Mei-Zahav, Meir, et al.
Publicado: (2017)

Tacrolimus in Gastrointestinal Bleeding in a Young Boy With Hereditary Hemorrhagic Telangiectasia
por: Pruijsen, Jessica M., et al.
Publicado: (2021)

Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report
por: Villanueva, Bernat, et al.
Publicado: (2023)

Future treatments for hereditary hemorrhagic telangiectasia
por: Robert, Florian, et al.
Publicado: (2020)

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
por: Cheloff, Abraham Z., et al.
Publicado: (2020)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding
por: Albiñana, Virginia, et al.
Publicado: (2020)

Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings
por: Mora-Luján, José María, et al.
Publicado: (2019)

Functional Alterations Involved in Increased Bleeding in Hereditary Hemorrhagic Telangiectasia Mouse Models
por: Egido-Turrión, Cristina, et al.
Publicado: (2022)

The bleeding diathesis in patients with hereditary haemorrhagic telangiectasia is not due to impaired platelet function
por: Lyster, Anne Lørup, et al.
Publicado: (2023)

Obstetrical and neonatal complications in hereditary haemorrhagic telangiectasia: A retrospective study
por: Delagrange, Laura, et al.
Publicado: (2022)

Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Torres-Iglesias, Raquel, et al.
Publicado: (2023)

Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia
por: Guilhem, Alexandre, et al.
Publicado: (2021)

Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia
por: Colombo, G., et al.
Publicado: (2016)

Prevalence and risk factors for bleeding in hereditary hemorrhagic telangiectasia: a National Inpatient Sample study
por: Zarka, Jabra, et al.
Publicado: (2023)

To Bleed or Not to Bleed
por: Iskander, Peter A, et al.
Publicado: (2023)

Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
por: Mei-Zahav, Meir, et al.
Publicado: (2020)

Pulmonary hypertension in hereditary haemorrhagic telangiectasia is associated with multiple clinical conditions
por: Margelidon-Cozzolino, Victor, et al.
Publicado: (2021)

Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study
por: Hessels, Josefien, et al.
Publicado: (2022)

Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
por: Hasan Albitar, Hasan Ahmad, et al.
Publicado: (2020)

Protein Pull-down Assay Using HiBiT-tag-dependent Luciferase Activity Measurement
por: Arakawa, Masashi, et al.
Publicado: (2023)

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uq3br758upjeaqrklebmompir8